Maravai LifeSciences Holdings (MEX:MRVI) EBIT: MXN-3,001 Mil (TTM As of Mar. 2026)


MEX:MRVI Maravai LifeSciences Holdings Inc MEX:MRVI
62 GF Score
Price MXN85.00
GF Value MXN53.06
! 8 Warning Signs
View Full Analysis

What is Maravai LifeSciences Holdings EBIT?

Maravai LifeSciences Holdings MEX:MRVI 62 EBIT is MXN-3,001 Mil as of Mar. 2026. GuruFocus rates MEX:MRVI with a GF Score™ of 62/100 and a GF Value™ of MXN53.06. The stock has 8 warning signs investors should review.

Maravai LifeSciences Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was MXN-14 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-3,001 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Maravai LifeSciences Holdings's annualized ROC % for the quarter that ended in Mar. 2026 was 0.54%. Maravai LifeSciences Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1.43%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Maravai LifeSciences Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -14.65%.

Maravai LifeSciences Holdings  (MEX:MRVI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Maravai LifeSciences Holdings's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=51.936 * ( 1 - 2.31% )/( (9704.316 + 9198.714)/ 2 )
=50.7362784/9451.515
=0.54 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=13874.778 - 265.206 - ( 3905.256 - max(0, 808.762 - 5334.207+3905.256))
=9704.316

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=12861.228 - 670.492 - ( 2992.022 - max(0, 768.59 - 4539.48+2992.022))
=9198.714

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Maravai LifeSciences Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-56.188/( ( (3434.389 + max(875.888, 0)) + (2649.545 + max(876.966, 0)) )/ 2 )
=-56.188/( ( 4310.277 + 3526.511 )/ 2 )
=-56.188/3918.394
=-1.43 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(459.109 + 729.141 + 240.701) - (265.206 + 53.783 + 234.074)
=875.888

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(602.563 + 729.639 + 215.256) - (670.492 + 0 + 1.1368683772162E-13)
=876.966

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Maravai LifeSciences Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-3000.609/20484.010
=-14.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maravai LifeSciences Holdings EBIT Related Terms

Maravai LifeSciences Holdings EBIT Historical Data

* Premium members only.

The historical data trend for Maravai LifeSciences Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maravai LifeSciences Holdings EBIT Chart

Maravai LifeSciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 11,508.87 11,149.49 11,264.59 -4,458.57 -3,744.86

Maravai LifeSciences Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -939.30 -1,267.39 -702.68 -1,016.49 -14.05

MEX:MRVI vs ANRO, BBOT, REPL: EBIT Comparison

For the Biotechnology subindustry, Maravai LifeSciences Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maravai LifeSciences Holdings EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Maravai LifeSciences Holdings's EV-to-EBIT falls into.


MEX:MRVI
62GF Score
Maravai LifeSciences Holdings Inc MEX:MRVI
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maravai LifeSciences Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-3,001 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of MXN-3,001 Mil mean?
Maravai LifeSciences Holdings (MEX:MRVI) has a EBIT of MXN-3,001 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Maravai LifeSciences Holdings.
Is Maravai LifeSciences Holdings' EBIT too high?
Maravai LifeSciences Holdings' current EBIT is MXN-3,001 Mil. Overall, Maravai LifeSciences Holdings has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Maravai LifeSciences Holdings' EBIT compare to ANRO and BBOT?
Maravai LifeSciences Holdings' EBIT of MXN-3,001 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Maravai LifeSciences Holdings. Maravai LifeSciences Holdings's current EBIT is MXN-3,001 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maravai LifeSciences Holdings stock overvalued right now?
Maravai LifeSciences Holdings (MEX:MRVI) has a current EBIT of MXN-3,001 Mil. The stock's GF Value™ is MXN53.06, compared to a current price of MXN85.00 — trading 60.2% above its estimated fair value. The current EBIT is MXN-3,001 Mil. Maravai LifeSciences Holdings' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Maravai LifeSciences Holdings (MEX:MRVI), the current EBIT is MXN-3,001 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Maravai LifeSciences Holdings (MEX:MRVI) Overvalued in 2026?

Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued. The current stock price of MXN85.00 is trading 60.2% above its estimated GF Value™ of MXN53.06.

Key valuation signals for MEX:MRVI:

  • EBIT: MXN-3,001 Mil
  • GF Value™: MXN53.06 vs. price of MXN85.00 (60.2% above fair value)
  • GF Score™: 62/100 with 8 warning signs

No single metric tells the full story. See the MEX:MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Maravai LifeSciences Holdings Business Description

Other Exchanges MRVI:USAMAR:Germany
Address 10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
62GF Score

Get the complete analysis for MEX:MRVI

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN85.00
Price
MXN53.06
GF Value